Data analysis in a study by the Israeli Health Ministry and Pfizer Inc found the Pfizer vaccine developed with Germany’s BioNTech reduces infection, including in asymptomatic cases, by 89.4% and in syptomatic cases by 93.7%.
Findings of the pre-published study, not yet peer-reviewed, but based on a national database that is one of the world’s most advanced.
A separate study by Israel’s Sheba Medical Center published on Friday in The Lancet medical journal found that among 7,214 hospital staff who received their first dose in January, there was an 85% reduction in symptomatic Covid-19 within 15 to 28 days with an overall reduction of infections, including asymptomatic cases detected by testing, of 75%.
More research is needed to draw a definitive conclusion, but the studies are among the first to suggest a vaccine may stop the spread of the novel coronavirus and not just prevent people getting ill.
Earlier, Pfizer CEO Albert Bourla said the company expects to double its rollout of coronavirus vaccines to 10 million a week. Pfizer now produces about 5 million doses a week.
US President Joe Biden on Friday secured a commitment from Pfizer Inc to double the Covid-19 vaccine it churns out in the coming weeks.
"In the next couple weeks, supply will increase from 5 million to 10 million doses per week," Biden said.
Biden, addressing media and other visitors to the plant, said his administration was on track with its goal to vaccinate 100 million Americans in its first 100 days, and also distribute 600 million doses by July 29.